Skip to content
NeuroTechGuide

PRIMA retinal implant shows vision gains holding at three years

Three-year data from the European PRIMAvera trial, presented at AAO 2026, show a mean gain of about 30 letters, with most serious adverse events in the first six months.

In briefImplantsClinical trials

Three-year results for Science Corp.’s PRIMA retinal implant were presented at the American Academy of Ophthalmology 2026 meeting. PRIMAvera implanted 38 people with advanced geographic atrophy at European sites. Participants started with central vision around 20/460, and mean acuity gains with the device reached about 30 letters at 36 months, up from about 25 at 12 months. There were 29 serious adverse events, and about 83% of them happened in the first six months after surgery. Most were tied to the surgery itself, such as pressure spikes or retinal bleeding.

The results suggest the early benefit lasts. The trial was small and had no control group, and the summaries do not say how many participants were assessed at three years. PRIMA has had a CE mark in Europe since July 2026; FDA review is still ongoing.

Learn more: Visual prosthesis · Science Corp.

Share:XLinkedInBlueskyEmail

More news